Agenus (NASDAQ:AGEN) Reaches New 12-Month Low at $8.10

Shares of Agenus Inc. (NASDAQ:AGEN) hit a new 52-week low on Friday . The stock traded as low as $8.10 and last traded at $8.16, with a volume of 93931 shares changing hands. The stock had previously closed at $8.87.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AGEN shares. StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a report on Sunday, March 24th. B. Riley lowered their price target on Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $160.00 price target on shares of Agenus in a research report on Thursday, March 14th.

Agenus Stock Performance

The stock has a market cap of $3.12 billion, a P/E ratio of -11.55 and a beta of 1.26. The firm has a 50-day moving average price of $0.63 and a 200-day moving average price of $0.74.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $54.21 million. On average, research analysts predict that Agenus Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at Agenus

In related news, insider Garo H. Armen acquired 25,000 shares of Agenus stock in a transaction that occurred on Thursday, February 15th. The stock was bought at an average price of $13.00 per share, with a total value of $325,000.00. Following the transaction, the insider now directly owns 31,298 shares in the company, valued at $406,874. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. boosted its stake in Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 2,232,064 shares during the last quarter. Swiss National Bank boosted its stake in Agenus by 5.9% during the 3rd quarter. Swiss National Bank now owns 690,100 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 38,600 shares during the last quarter. Citigroup Inc. boosted its stake in Agenus by 41.0% during the 3rd quarter. Citigroup Inc. now owns 707,213 shares of the biotechnology company’s stock valued at $799,000 after purchasing an additional 205,817 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Agenus by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 27,137 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Agenus by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 107,291 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 15,370 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.